drugset / Trial / NCT00222144
Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer
Phase 2
Completed
23 enrolled
University of Kansas
Kansas Masonic Cancer Research Institute · collabNovartis · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary goal of this study is to determine the effects of the combination of Gleevec and Taxotere in lung cancer in terms of control and reduction of the cancer size. The study will also test lung cancer to see if the presence of certain protein called receptor for platelet derived growth factor can influence the effect of the treatment.
Timeline
- Start
- 2004-09
- Primary completion
- 2010-11
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Imatinib | Small molecule | 600 mg | — |